Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial

PURPOSE: The role of immunotherapy in hormone receptor (HR)-positive, HER2-negative breast cancer is underexplored. PATIENTS AND METHODS: The neoadjuvant phase II GIADA trial (NCT04659551, EUDRACT 2016-004665-10) enrolled stage II–IIIA premenopausal patients with Luminal B (LumB)-like breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieci, Maria Vittoria, Guarneri, Valentina, Tosi, Anna, Bisagni, Giancarlo, Musolino, Antonino, Spazzapan, Simon, Moretti, Gabriella, Vernaci, Grazia Maria, Griguolo, Gaia, Giarratano, Tommaso, Urso, Loredana, Schiavi, Francesca, Pinato, Claudia, Magni, Giovanna, Lo Mele, Marcello, De Salvo, Gian Luca, Rosato, Antonio, Conte, Pierfranco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401542/
https://www.ncbi.nlm.nih.gov/pubmed/34667023
http://dx.doi.org/10.1158/1078-0432.CCR-21-2260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401542/
https://www.ncbi.nlm.nih.gov/pubmed/34667023
http://dx.doi.org/10.1158/1078-0432.CCR-21-2260

Ejemplares similares